Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aldeyra Therapeutics, Inc.ALDX · Entity 6839 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aldeyra Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08 | Direct | 70,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 70,000 · Balance 70,000 F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08 | Direct | 5,309 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 5,309 · Balance 5,309 F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08 | Direct | 4,977 |
Reported balance
After 2026-06-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-09 · Grant · Acquired 4,977 · Balance 4,977 F3: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date.
F3: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 20:20 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 4,977 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001193125-26-267600 · ownership.xml · derivative · entry 3 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,977 Underlying: Common Stock · 4,977 shares Expires 2036-06-08 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:20 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 5,309 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001193125-26-267600 · ownership.xml · derivative · entry 2 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,309 Underlying: Common Stock · 5,309 shares Expires 2036-06-08 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:20 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001193125-26-267600 · ownership.xml · derivative · entry 1 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-06-08 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:29 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 3,619 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0000950170-25-085454 · ownership.xml · derivative · entry 2 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,619 Underlying: Common Stock · 3,619 shares Expires 2035-06-09 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:29 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 62,728 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0000950170-25-085454 · ownership.xml · derivative · entry 1 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,728 Underlying: Common Stock · 62,728 shares Expires 2035-06-09 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 10, 2024 Filed Jun 12, 2025 20:29 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 3,860 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0000950170-25-085454 · ownership.xml · derivative · entry 3 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,860 Underlying: Common Stock · 3,860 shares Expires 2035-06-09 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:12 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 2,778 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0000950170-24-069885 · ownership.xml · derivative · entry 3 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,778 Underlying: Common Stock · 2,778 shares Expires 2034-06-03 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:12 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 2,604 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0000950170-24-069885 · ownership.xml · derivative · entry 2 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,604 Underlying: Common Stock · 2,604 shares Expires 2034-06-03 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:12 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 40,282 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0000950170-24-069885 · ownership.xml · derivative · entry 1 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,282 Underlying: Common Stock · 40,282 shares Expires 2034-06-03 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:34 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 1,464 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000950170-23-031781 · ownership.xml · derivative · entry 3 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,464 Underlying: Common Stock · 1,464 shares Expires 2033-06-29 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:34 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 1,372 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000950170-23-031781 · ownership.xml · derivative · entry 2 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,372 Underlying: Common Stock · 1,372 shares Expires 2033-06-29 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:34 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 21,222 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000950170-23-031781 · ownership.xml · derivative · entry 1 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,222 Underlying: Common Stock · 21,222 shares Expires 2033-06-29 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 20:23 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,604 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0000899243-23-016709 · doc4.xml · derivative · entry 2 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,604 shares Expires 2023-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 20:23 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | Exercise / conversionCommon Stock | 9,604 | $0.55 | $5,301.41 |
DisclosureSEC source: 0000899243-23-016709 · doc4.xml · nonDerivative · entry 1 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:06 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 3,711 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0000899243-22-021632 · doc4.xml · derivative · entry 3 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,711 Underlying: Common Stock · 3,711 shares Expires 2032-06-06 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:06 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 3,479 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0000899243-22-021632 · doc4.xml · derivative · entry 2 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,479 Underlying: Common Stock · 3,479 shares Expires 2032-06-06 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:06 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 53,812 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0000899243-22-021632 · doc4.xml · derivative · entry 1 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,812 Underlying: Common Stock · 53,812 shares Expires 2032-06-06 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 21:44 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 933 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0000899243-21-023007 · doc4.xml · derivative · entry 3 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 933 Underlying: Common Stock · 933 shares Expires 2031-06-07 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 21:44 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 875 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0000899243-21-023007 · doc4.xml · derivative · entry 2 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875 Underlying: Common Stock · 875 shares Expires 2031-06-07 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 21:44 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 13,534 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0000899243-21-023007 · doc4.xml · derivative · entry 1 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,534 Underlying: Common Stock · 13,534 shares Expires 2031-06-07 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 21:51 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 1,541 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0000899243-20-016185 · doc4.xml · derivative · entry 3 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,541 Underlying: Common Stock · 1,541 shares Expires 2030-06-08 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 21:51 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 2,311 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0000899243-20-016185 · doc4.xml · derivative · entry 2 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,311 Underlying: Common Stock · 2,311 shares Expires 2030-06-08 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 21:51 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 26,503 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0000899243-20-016185 · doc4.xml · derivative · entry 1 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,503 Underlying: Common Stock · 26,503 shares Expires 2030-06-08 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 20:23 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | PurchaseCommon Stock | 1,700 | $5.85 | $9,945.00 |
DisclosureSEC source: 0000899243-19-023923 · doc4.xml · nonDerivative · entry 1 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,644 Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 21:41 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,102 | $0.00 Strike: $7.06 | $0.00 |
DisclosureSEC source: 0000899243-19-015824 · doc4.xml · derivative · entry 3 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,102 Underlying: Common Stock · 1,102 shares Expires 2029-06-03 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 21:41 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,653 | $0.00 Strike: $7.06 | $0.00 |
DisclosureSEC source: 0000899243-19-015824 · doc4.xml · derivative · entry 2 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,653 Underlying: Common Stock · 1,653 shares Expires 2029-06-03 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 21:41 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,951 | $0.00 Strike: $7.06 | $0.00 |
DisclosureSEC source: 0000899243-19-015824 · doc4.xml · derivative · entry 1 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,951 Underlying: Common Stock · 18,951 shares Expires 2029-06-03 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:38 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 903 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0000899243-18-015771 · doc4.xml · derivative · entry 3 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 903 Underlying: Common Stock · 903 shares Expires 2028-06-06 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:38 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,354 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0000899243-18-015771 · doc4.xml · derivative · entry 2 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,354 Underlying: Common Stock · 1,354 shares Expires 2028-06-06 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:38 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 15,526 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0000899243-18-015771 · doc4.xml · derivative · entry 1 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,526 Underlying: Common Stock · 15,526 shares Expires 2028-06-06 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:07 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 1,481 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0000899243-17-016105 · doc4.xml · derivative · entry 3 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,481 Underlying: Common Stock · 1,481 shares Expires 2027-06-07 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:07 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 2,222 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0000899243-17-016105 · doc4.xml · derivative · entry 2 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,222 Underlying: Common Stock · 2,222 shares Expires 2027-06-07 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:07 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 17,776 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0000899243-17-016105 · doc4.xml · derivative · entry 1 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,776 Underlying: Common Stock · 17,776 shares Expires 2027-06-07 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 21:31 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | PurchaseCommon Stock | 4,444 | $4.50 | $19,998.00 |
DisclosureSEC source: 0000899243-17-004753 · doc4.xml · nonDerivative · entry 1 Bronstein Ben · CIK 0001604458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,944 F1 · price: Represents shares of common stock purchased by the Reporting Person in the Issuer's follow-on offering, which closed on February 17, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.